For healthcare professionals and researchers only. ClinicalMind content does not constitute clinical guidance, diagnosis, or treatment advice. See full disclaimer
Plain-language summaries and structured analyses of significant primary research papers on AI in healthcare, drawn from peer-reviewed journals including NEJM AI, JAMA, Nature Medicine, npj Digital Medicine, and Lancet Digital Health. Each entry provides structured key takeaways, methodology overview, study population, performance metrics, limitations, funding and conflict-of-interest disclosures, and links to the original publication (DOI/PMID). This group serves researchers, clinicians, and evidence-seeking readers who need efficient access to what the literature actually shows — without reproducing copyrighted text. Excludes opinion, vendor-sourced claims, and non-peer-reviewed preprints unless clearly labeled as such. Does not provide clinical guidance or treatment recommendations.
Study Types
Journals
Clinical Application Areas
A structured synthesis of 128+ PubMed-indexed studies published between 2023 and 2026 evaluating ambient AI documentation tools — including deployments at health systems where Nuance DAX, Suki, and Abridge operate — for clinicians, informaticists, and health system leaders who need an evidence-grounded assessment beyond vendor claims.
A structured evidence appraisal of Raciti et al. 2023 (Arch Pathol Lab Med, PMID 36538386) — the pivotal multi-reader, multi-case reader study underpinning FDA De Novo authorization DEN200080 for Paige Prostate — examining study design, reported performance, industry conflict of interest, and the limitations that restrict direct translation of these findings to real-world clinical deployment. Intended for pathologists, urologic oncologists, clinical researchers, and health system administrators evaluating the quality of the evidence before adoption or procurement decisions.
A structured digest of McGenity et al. (npj Digital Medicine, 2024) — the first systematic review and meta-analysis of AI diagnostic accuracy across whole slide images spanning multiple disease areas — examining what the headline performance figures of 96.3% mean sensitivity and 93.3% mean specificity actually represent, and why 99% of included studies carry high or unclear risk of bias under QUADAS-2 assessment. For pathologists, oncologists, laboratory administrators, and clinical researchers who need an evidence-grounded appraisal before interpreting AI pathology performance claims.
A structured digest of the BMJ Open 2025 systematic review (31 studies, 2 million+ screening examinations) and the highest-tier 2025–2026 prospective evidence — MASAI, GEMINI, and AIMS — evaluating AI performance in breast cancer screening programs, for radiologists, breast imaging clinicians, and clinical researchers who need a rigorous evidence synthesis without reading the full primary papers.
A structured digest of Sattar et al. (Cureus, 2025), the first PRISMA-aligned systematic review and meta-analysis restricted exclusively to GI Genius RCTs (7 trials, n=9,639), covering pooled effect sizes for ADR, SSLDR, and advanced adenoma detection with GRADE-rated certainty — for gastroenterologists and hospital technology committees evaluating device-specific evidence before or after adoption.
A curated set of structured research notices tracking recently published peer-reviewed studies and active preprints on AI-assisted medical diagnosis across radiology, pathology, cardiology, and primary care. Each entry records study type, primary finding, and an editorial note on tracking priority.
A structured analysis of randomized controlled trial evidence for AI-assisted colonoscopy polyp detection, covering adenoma detection rates, study design limitations, population representativeness gaps, and what the current evidence base does and does not support for clinical adoption.
A structured analysis of the randomized controlled trial evidence, diagnostic accuracy meta-analysis, and real-world performance data for autonomous AI diabetic retinopathy screening systems — covering the three FDA-cleared devices, key heterogeneity drivers, and unresolved deployment gaps as of Q2 2026. Intended for clinicians, researchers, and health system professionals evaluating or monitoring this technology.
A structured review of peer-reviewed evidence on AI applications across clinical medicine — covering study designs, performance metrics, external validation gaps, and what the literature does and does not yet support.
A structured overview of where generative AI stands in healthcare as of mid-2026 — covering LLM performance on clinical tasks, documented failure modes, regulatory status, and the gap between research demonstrations and deployed clinical tools.
A structured overview of how AI is being applied across healthcare — covering the regulatory landscape, clinical evidence quality, deployment realities, and the specific gaps that practitioners and researchers need to understand before acting on AI claims.
A structured analysis of peer-reviewed evidence on AI applications across clinical medicine — covering study designs, performance benchmarks, external validation gaps, and the limitations practitioners need to understand before drawing conclusions from published findings.
A structured synthesis of peer-reviewed studies published through mid-2026 examining LLM-based ambient AI scribe performance in clinical documentation — covering efficacy findings from four major studies, a quantified error taxonomy from the UC Davis Health pilot, evidence quality limitations, regulatory status, and the substantial gaps that remain before findings can be generalized beyond ambulatory primary care.
A structured notice digest of peer-reviewed studies, prospective validations, and clinical trial results in medical artificial intelligence published through Q2 2026 — covering imaging AI, LLMs in clinical settings, bias audits, and ambient documentation tools.
A structured synthesis of how algorithmic bias originates and propagates through clinical AI systems, drawing on peer-reviewed evidence of disparate performance across care domains, three major audit frameworks operating at distinct governance levels, and technical and systemic mitigation strategies — with current U.S. regulatory context for health system leaders and researchers.
A structured methodological appraisal of the Wong et al. 2026 JAMA Network Open study — the first large-scale multicenter prospective external validation of Epic Sepsis Model version 2 across 227,091 inpatient encounters — examining study design quality, statistical findings by site, acknowledged limitations, and the boundaries of what this evidence can and cannot support.
A structured evidence review of Lunit INSIGHT MMG, an FDA-cleared deep learning AI-CAD system for screening mammography, covering the ScreenTrustCAD (Lancet Digital Health, 2023) and AI-STREAM (Nature Communications, 2025) prospective studies, real-world deployment data, known limitations, and workflow-specific clinical implications — including a correction of the common misattribution of the MASAI RCT to this product.
